Patents by Inventor Paul D. Rennert
Paul D. Rennert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150110792Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.Type: ApplicationFiled: November 16, 2012Publication date: April 23, 2015Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
-
Patent number: 8287874Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.Type: GrantFiled: June 10, 2010Date of Patent: October 16, 2012Assignee: Biogen Idec MA Inc.Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
-
Publication number: 20120156214Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.Type: ApplicationFiled: June 10, 2010Publication date: June 21, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Jeffrey L. BROWNING, Paula S. HOCHMAN, Paul D. RENNERT, Fabienne MACKAY
-
Patent number: 7744891Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.Type: GrantFiled: August 13, 2007Date of Patent: June 29, 2010Assignee: Biogen Idec MA Inc.Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
-
Publication number: 20100080798Abstract: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-? by lymphocytes or other immune cells in a mammal. Inhibition of IFN-? is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.Type: ApplicationFiled: August 26, 2009Publication date: April 1, 2010Applicant: BIOGEN IDEC MA INC.Inventor: Paul D. Rennert
-
Patent number: 7597887Abstract: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-? by lymphocytes or other immune cells in a mammal. Inhibition of IFN-? is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.Type: GrantFiled: December 29, 2003Date of Patent: October 6, 2009Assignee: Biogen Idec MA Inc.Inventor: Paul D. Rennert
-
Publication number: 20090155836Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: ApplicationFiled: October 22, 2008Publication date: June 18, 2009Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, GENETICS INSTITUTE, LLC, The United States of America as Represented by the Secretary of the NavyInventors: Carl H. JUNE, Craig B. THOMPSON, Gary J. NABEL, Gary S. GRAY, Paul D. RENNERT
-
Patent number: 7479269Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 5, 2006Date of Patent: January 20, 2009Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Publication number: 20080219967Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.Type: ApplicationFiled: August 13, 2007Publication date: September 11, 2008Applicant: Biogen Idec MA Inc.Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne MacKay
-
Patent number: 7309492Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.Type: GrantFiled: October 31, 2001Date of Patent: December 18, 2007Assignee: Biogen Idec MA Inc.Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne MacKay
-
Patent number: 7255854Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.Type: GrantFiled: April 23, 1999Date of Patent: August 14, 2007Assignee: Biogen, Inc.Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
-
Patent number: 7232566Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 4, 2005Date of Patent: June 19, 2007Assignees: The United States as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLCInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7175843Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: March 2, 2006Date of Patent: February 13, 2007Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7144575Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: March 17, 2003Date of Patent: December 5, 2006Assignees: The Regents of the University of Michigan, Genetics Institute, LLC, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6905681Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: July 8, 1999Date of Patent: June 14, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6905680Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 26, 1996Date of Patent: June 14, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6887466Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: July 8, 1999Date of Patent: May 3, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Publication number: 20040202650Abstract: Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed.Type: ApplicationFiled: December 9, 2003Publication date: October 14, 2004Inventors: John G. Gribben, Gordon J. Freeman, Lee M. Nadler, Paul D. Rennert, Cindy L. Jellis, Edward Greenfield, Gary S. Gray
-
Publication number: 20040151725Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: ApplicationFiled: March 2, 2004Publication date: August 5, 2004Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
-
Patent number: 6750334Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.Type: GrantFiled: February 2, 1996Date of Patent: June 15, 2004Assignee: Repligen CorporationInventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver